Moleculin Biotech, Inc. Income Statement
MBRX|10 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Moleculin Biotech, Inc. reported $0 in revenue and $26M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $8.8M | $10.0M | $11.5M | $8.4M | $6.8M | $6.3M | $5.2M | $4.1M | $2.4M | $477.8K |
| R&D Expense | $17.7M | $19.5M | $19.0M | $14.4M | $12.8M | $11.0M | $9.7M | $4.5M | $1.5M | $260.4K |
| Operating Income | -$26.6M | -$29.6M | -$30.6M | -$23.0M | -$19.7M | -$17.5M | -$15.0M | -$8.7M | -$3.9M | -$738.2K |
| Interest Expense | - | - | - | $306.0K | $13.0K | $13.0K | $4.0K | $0 | $43.0K | $10.1K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | -$229.0K | $0 | $0 | $0 | $0 |
| Net Income | -$26.0M | -$29.8M | -$29.0M | -$15.9M | -$17.4M | -$13.2M | -$11.9M | -$9.8M | -$3.9M | -$748.4K |
| EPS (Basic) | -$189.14 | -$15.07 | -$15.22 | -$0.59 | - | - | - | - | - | - |
| EPS (Diluted) | - | - | - | - | -$1.76 | -$1.95 | -$0.46 | -$0.53 | -$0.40 | -$0.13 |
| Shares Outstanding | 135.2K | 2.2M | 1.9M | - | 11.5M | 7.6M | 28.5M | 21.5M | 12.2M | 6.7M |